The platform aims to improve physician experience, diagnostic accuracy, treatment, financial performance, and patient outcomes. Arterys' product has been integrated into Tempus' solutions, enabling providers to access a comprehensive patient view inclusive of radiology scans and researchers to leverage this data modality to optimize the drug development process.
Cyborg Score Rationale
Arterys delivers clinically-validated AI-driven radiology analytics with strong enterprise integration capabilities and now benefits from Tempus' broader precision medicine platform. The acquisition provides capital backing and expanded distribution, though post-acquisition integration execution and standalone competitive positioning remain key uncertainties.
Top Insights
Founded in 2012 by Shreyas Vasanawala and Fabien Beckers; raised $70.2M in funding from investors including Temasek, Emergent Medical Partners, and General Electric
Integrates AI clinical applications into existing radiology workflows with cloud-based GPU architecture for real-time multi-AI execution
Acquired by Tempus in November 2022, now integrated into Tempus Radiology as part of broader precision medicine strategy
Top competitors include HeartFlow, Cleerly, and Lantheus